AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06661343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C4 Program
Description: The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
Study NCT06661343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C4 + 3MV Program
Description: This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
Study NCT06658925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Description: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
Study NCT06659120 — intervention group
Intervention type: DRUG
Intervention: Fremanezumab
Description: Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
Study NCT04974827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/3weeks
Study NCT04974827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
Study NCT05365997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default Nudge
Description: For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
Study NCT05434429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
Study NCT05252117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
Study NCT06550258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-assisted therapy
Description: Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.
Study NCT06550258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Pediatric Physiotherapy
Description: In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
Study NCT05642845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin film-coated tablet 40 mg
Description: Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
Study NCT05642845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liprimar® film-coated tablet 40 mg
Description: Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin.
Study NCT04868968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFV890
Description: 100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
Study NCT05575258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 44-Day Diet Conventionally Sourced - YELLOW Diet
Description: Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
Study NCT05575258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 44-Day Diet Agro-Ecologically Sourced - GREEN Diet
Description: Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
Study NCT04869215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EverVita Pro
Description: EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
Study NCT04869215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Bread baked with normal Bakers flour
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regime A (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 2 Regimen C (Pindolol)
Description: Drug: Pindolol tablets for oral use.
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group D (Pindolol)
Description: Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group E (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT06558565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stromal vascular fraction or platelet rich plasma
Description: stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group F (ACM-001.1 )
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 Group G (ACM-001.1)
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT06028321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regimen B (Pindolol)
Description: Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Study NCT06028321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 1 Group 1 Regimen A (Placebo)
Description: Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Study NCT06028321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 2 Group E (Placebo)
Description: Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT06204510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex decongestive therapy
Description: This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.
Study NCT06028321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 2 Group F (Placebo)
Description: Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT06028321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part 2 Group G ( Placebo)
Description: Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study NCT05183152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES Feedback
Description: Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
Study NCT05183152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
Study NCT05183152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Feedback
Description: Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
Study NCT05183152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESS
Description: Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
Study NCT06359106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 80% Oxygen
Description: After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
Study NCT06359106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40% Oxygen
Description: After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
Study NCT04670887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed surgery
Description: Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
Study NCT04670887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate surgery
Description: Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
Study NCT05308069 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single vision contact lens
Description: Subjects will wear a single vision soft contact lens only during the study visit
Study NCT05308069 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multifocal contact lens
Description: Subjects will wear a multifocal soft contact lens only during the study visit
Study NCT05875987 — intervention group
Intervention type: DEVICE
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT06473077 — intervention group
Intervention type: PROCEDURE
Intervention: ETT beyond C7 level
Description: Endotracheal cuff is placed deeper beyond C7 level, but above carina
Study NCT05243784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-HIIT intervention
Description: Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities.
Study NCT06335160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
Study NCT02930811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg oral morning dose
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months
Study NCT02930811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral morning dose
Description: Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months
Study NCT05228028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia iliaca compartement block
Description: Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
Study NCT05228028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block
Description: Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
Study NCT05039138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEUROMUSCULAR TRAINING EXERCISE
Description: patients will receive neuromuscular training exercises in group II
Study NCT05039138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional training exerises
Description: traditional strength training exercises in group I
Study NCT03496610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivicaine
Description: Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
Study NCT03496610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Patient will receive ultrasound guided QL Block
Study NCT06321887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)
Description: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
Study NCT06321887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)
Description: Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
Study NCT06321887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)
Description: Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
Study NCT05886829 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpheniramine Maleate 0.4% Nasal Spray
Description: Chlorpheniramine Maleate 0.4% Nasal Spray
Study NCT06505941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: umbilical cord mesenchymal stem cell
Study NCT06505941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-cell-containing placebo
Study NCT05252598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 1mg encapsulated psilocybin
Study NCT05252598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inonotus Obliquus Whole Extract
Description: 1mg encapsulated chaga mushroom
Study NCT05776251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold.
Study NCT05540028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVT PCV-25
Description: 25 valent pneumococcal conjugate vaccine
Study NCT05540028 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 20
Description: 20 valent pneumococcal conjugate vaccine
Study NCT05487534 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
Study NCT06032650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics exercise and High intensity interval training
Description: 1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax
Study NCT04889287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Once daily over 12 days
Study NCT04889287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single doses on Day 1, Day 8, and Day 13
Study NCT05419609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited facelift
Description: A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
Study NCT05419609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full facelift
Description: A full face and neck lift that addresses signs of aging in the face and neck
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline
Description: Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline.